TICKERNERD
Menu
FHTXFHTXHealthcare · Biotechnology

FHTX Stock Forecast: Foghorn Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$1.99
−4.78% on the day

The 10 Wall Street analysts covering Foghorn Therapeutics, Inc. hold a median 12-month price target of $5 — +151.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$117.0M
Ticker Nerd rank
40 / 100
Median analyst target
$5.00
Analysts covering
10
Revenue$16.1M+112.7% y/y
Operating income−$8.8M
Net income−$7.2M
Free cash flow−$17.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−31.8%
1M
−58.8%
YTD
−63.1%
1Y
−55.8%
From 52W high
−71.9%
From 52W low
+1.0%
$1.97
$7.07
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FHTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Foghorn Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
91
Size
73
Revisions
66
Quality
57
Volatility
42
Accruals
41
Momentum
20
Value
19
Issuance
14

Growth (91): Sales and profits are climbing, and climbing faster than before.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FHTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FHTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Jan 26Apr 26Jul 26Oct 26FHTXHigh $14.00Median $5.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
6 Buy4 Hold0 Sell
Low $2.00Median $5.00High $14.00

The green dot is the last close — the median target sits +151.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
2 Oct 2026BTIGDowngradeNeutral—
2 Oct 2026GuggenheimMaintainsBuy$12 → $5.00
2 Oct 2026HC Wainwright & Co.MaintainsBuy$13 → $5.00
2 Oct 2026TD CowenDowngradeHold—
2 Oct 2026WedbushDowngradeNeutral$10 → $2.00
12 Mar 2026WedbushReiteratesOutperform—
12 Mar 2026WedbushReiteratesOutperform$10
10 Mar 2026HC Wainwright & Co.ReiteratesBuy—
10 Mar 2026HC Wainwright & Co.ReiteratesBuy$13
17 Feb 2026JefferiesMaintainsBuy—
18 Dec 2025BTIGInitiatesBuy—
4 Dec 2025StifelInitiatesBuy—
7 Nov 2025GuggenheimInitiatesBuy—
15 May 2025JMP SecuritiesReiteratesMarket Outperform—
30 Apr 2025HC Wainwright & Co.ReiteratesBuy—
30 Apr 2025JMP SecuritiesReiteratesMarket Outperform—
23 Apr 2025JMP SecuritiesInitiatesMarket Outperform—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
30 Jan 2025B. Riley SecuritiesInitiatesBuy—
17 Dec 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FHTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

FHTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Foghorn Therapeutics, Inc. returned −55.8% against +16.2% for the S&P 500, dividends included.

FHTX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26FHTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FHTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
7
Analysts cutting
0
Fundamentals

Foghorn Therapeutics, Inc. (FHTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.8×

Cheaper than 85% of US stocks

Price / sales
3.2×

Cheaper than 38% of US stocks

Price / book
−1.8×

Cheaper than 95% of US stocks

EV / EBITDA
0.1×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
112.7%

Higher than 93% of US stocks

Earnings growth (YoY)
112.7%

Higher than 85% of US stocks

Gross margin
—
Operating margin
−54.8%

Higher than 16% of US stocks

Net margin
−175.8%

Higher than 3% of US stocks

Returns & dividend
Return on equity
68.5%

Higher than 94% of US stocks

Return on assets
−19.9%

Higher than 19% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Foghorn Therapeutics, Inc. (FHTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Foghorn Therapeutics, Inc. has a market value of $117.0M and an enterprise value of −$7.5M.

  • Revenue in the twelve months to 30 June 2026: $36.7M. The latest quarter grew 112.7% year on year.

  • Net income over the same four quarters: −$64.6M, a −175.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$84.3M.

  • Shares outstanding: 58.7M.

  • Trailing P/E: −1.8×; forward P/E: −1.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Foghorn Therapeutics, Inc. employs 106 people — $347K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

FHTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FHTXFoghorn Therapeutics, Inc.$117.0M
40
COYACoya Therapeutics, Inc.$117.1M
64
HURATuHURA Biosciences, Inc.$117.2M
18
TNYATenaya Therapeutics, Inc.$117.8M
32
ENGNenGene Therapeutics, Inc.$114.9M
18
VTVTvTv Therapeutics, Inc.$118.5M
77
HUMAHumacyte, Inc.$120.6M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Foghorn Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FHTX news & analysis

Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal

Benzinga · 1 Oct 2026negative

Foghorn Therapeutics, Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with unusually high session volume of 9.158 million shares, compared to an average volume of 377,206, according to Benzinga Pro data. The company is pivoting its pipeline after ending its collaboration deal with Eli Lilly.

Why it matters — FHTX watchers would care because the stock is trading down on a sharp spike in volume following the company's pipeline pivot after the Eli Lilly deal ended, signaling significant investor reaction to the strategic shift.

Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug

Reuters · 1 Oct 2026negative

Foghorn Therapeutics has discontinued development of an experimental cancer drug partnered with Eli Lilly after the treatment failed to show sufficient benefit in an early-stage trial. The company also plans to cut 40% of its workforce.

Why it matters — The discontinuation of a Lilly-partnered drug and the large workforce reduction signal a major setback in Foghorn's pipeline and operations for shareholders and investors watching the company.

Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart

Barrons · 1 Oct 2026negative

Foghorn Therapeutics and Eli Lilly will not pursue any future collaborations following the dissolution of their cancer-drug partnership. As a result, Foghorn plans to cut roughly 40% of its workforce.

Why it matters — The end of the Lilly partnership and the significant job cuts signal a major restructuring and loss of a key collaboration for FHTX.

Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities

GlobeNewsWire · 1 Oct 2026negative

Foghorn Therapeutics and Lilly have decided not to advance the FHD-909 program into the clinical development expansion phase, based on a review of Phase 1 dose escalation data. The company will focus resources on its wholly owned pipeline, including a Selective EP300 degrader, an oral immunology/inflammation program, a Selective CBP degrader, and its induced proximity platform, and expects an approximately 40% workforce reduction with a cash runway extended into the second half of 2029.

Why it matters — A FHTX watcher would care because this news marks the discontinuation of a key collaborative program with Lilly, significant pipeline reprioritization, and a large workforce reduction, though it also extends the company's cash runway into the second half of 2029.

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet

Zacks Investment Research · 26 Aug 2026positive

Zacks reports that the consensus analyst price target for Foghorn Therapeutics (FHTX) implies about 67% upside potential. The piece notes that while price targets are not a highly reliable metric, an upward trend in earnings estimate revisions could signal near-term upside for the stock.

Why it matters — FHTX watchers would care because the article highlights both a bullish analyst price target and a positive shift in earnings estimate revisions, both of which are factors often tracked when evaluating the stock's near-term outlook.

FAQ

Frequently asked questions about FHTX stock

What is the FHTX stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Foghorn Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $2 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FHTX stock a buy right now?

Of the 10 analysts covering Foghorn Therapeutics, Inc., 6 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Foghorn Therapeutics, Inc. 40 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FHTX?

As at 8 Oct 2026, Foghorn Therapeutics, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (91 of 100).

Will FHTX stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +151.3% from the last close, and Ticker Nerd's factor model ranks Foghorn Therapeutics, Inc. 40 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FHTX stock forecast for 2030?

No analyst covering Foghorn Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FHTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $14 over the next 12 months.

How has FHTX stock performed over the past year?

Foghorn Therapeutics, Inc. returned -55.8% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Foghorn Therapeutics, Inc. do?

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines that correct abnormal gene expression.

What is the latest news on FHTX?

The most recent item we track (Benzinga, 1 Oct 2026): "Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal". Foghorn Therapeutics, Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with unusually high session volume of 9.158 million shares, compared to an average volume of 377,206, according to Benzinga Pro data. The company is pivoting its pipeline after ending its collaboration deal with Eli Lilly.

Company

About Foghorn Therapeutics, Inc.

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines that correct abnormal gene expression. Foghorn Therapeutics Inc. uses its proprietary Gene Traffic Control platform to study the chromatin regulatory system, a core mechanism that influences how genes are activated or silenced in cells. Its current programs are centered on oncology, with efforts directed at genetically defined cancers and other serious diseases linked to chromatin-driven dependencies. The company’s research and development activities include precision therapeutics designed to identify and validate drug targets within this regulatory network, supporting the creation of targeted treatments for hard-to-address diseases. Headquartered in Watertown, Massachusetts, Foghorn Therapeutics Inc. plays a specialized role in the biotechnology market as a developer of novel, mechanism-based therapies.

CEO Mr. Adrian H. B. Gottschalk · 106 employees · United States · https://foghorntx.com